Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

The Lancet Oncology

Volumn 18, Issue 5, 2017, Pages 640-653

  Thuss Patience, Peter C ^a   Shah, Manish A ^b   Ohtsu, Atsushi ^c   Van Cutsem, Eric ^d   Ajani, Jaffer A ^e   Castro, Hugo ^f   Mansoor, Wasat ^g   Chung, Hyun Cheol ^h   Bodoky, Gyorgy ⁱ   Shitara, Kohei ^j   Phillips, Gail D Lewis ^k   van der Horst, Tina ^l   Harle Yge, Marie Laurence ^l   Althaus, Betsy L ^k   Kang, Yoon Koo ^m  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Christie Hospital NHS Trust ^*  (Guatemala)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h Yonsei University College of Medicine   (South Korea)

ⁱ Szent Laszlo Hospital   (Hungary)

^j NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^k GENENTECH INC   (United States)

^l F HOFFMANN LA ROCHE LTD   (Switzerland)

^m University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; DOCETAXEL; PACLITAXEL; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY; TAXANE; TAXOID;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CONTROLLED STUDY; DECREASED APPETITE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL JUNCTION; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SENSORY NEUROPATHY; STOMACH ADENOCARCINOMA; STOMACH HEMORRHAGE; THROMBOCYTOPENIA; UPPER GASTROINTESTINAL BLEEDING; VERY ELDERLY; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; PATHOLOGY; RETREATMENT; SECONDARY; STOMACH NEOPLASMS; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRIDGED-RING COMPOUNDS; ESOPHAGOGASTRIC JUNCTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MAYTANSINE; MIDDLE AGED; PNEUMONIA; RECEPTOR, ERBB-2; RETREATMENT; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; THROMBOCYTOPENIA;

EID: 85017152115     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30111-0     Document Type: Article

References (35)

1. 1 GLOBOCAN Project (International Agency for Research on Cancer. Stomach cancer. Estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp, 2016 (accessed Nov 23).
2. 2 Van Cutsem, E, Bang, Y, Feng-yi, F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18 (2015), 476–484.
3. 3 Rüschoff, J, Hanna, W, Bilous, M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 25 (2012), 637–650.
4. 4 Gomez-Martin, C, Plaza, JC, Pazo-Cid, R, et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 31 (2013), 4445–4452.
5. 5 Bang, YJ, Van Cutsem, E, Feyereislova, A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010), 687–697.
6. 6 Janowitz, T, Thuss-Patience, P, Marshall, A, et al. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer 114 (2016), 381–387.
7. 7 Thuss-Patience, PC, Kretzschmar, A, Bichev, D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47 (2011), 2306–2314.
8. 8 Kang, JH, Lee, SI, Lim, DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30 (2012), 1513–1518.
9. 9 Ford, HE, Marshall, A, Bridgewater, JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15 (2014), 78–86.
10. 10 Hironaka, S, Ueda, S, Yasui, H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31 (2013), 4438–4444.
11. 11 Fuchs, CS, Tomasek, J, Yong, CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
12. 12 Wilke, H, Muro, K, Van Cutsem, E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15 (2014), 1224–1235.
13. 13 Satoh, T, Xu, RH, Chung, HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol 32 (2014), 2039–2049.
14. 14 Arai, T, Hamaguchi, T, Shirao, K, et al. Weekly paclitaxel in patients with heavily treated advanced gastric cancer. Proc Am Soc Clin Oncol, 22, 2003, 1291 (abstr).
15. 15 Kodera, Y, Ito, S, Mochizuki, Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG302 study). Anticancer Res 27 (2007), 2667–2671.
16. 16 Matsuda, G, Kunisaki, C, Makino, H, et al. Phase II study of weekly paclitaxel as a secondline treatment for S-1-refractory advanced gastric cancer. Anticancer Res 29 (2009), 2863–2867.
17. 17 Takiuchi, H, Fukuda, H, Boku, N, et al. Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). J Clin Oncol, 28, 2010, 4052 (suppl)(abstr).
18. 18 Lewis Phillips, GD, Li, G, Dugger, DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68 (2008), 9280–9290.
19. 19 Junttila, TT, Li, G, Parsons, K, Phillips, GL, Sliwkowski, MX, Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128 (2011), 347–356.
20. 20 Barok, M, Tanner, M, Koninki, K, Isola, J, Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 306 (2011), 171–179.
21. 21 Verma, S, Miles, D, Gianni, L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367 (2012), 1783–1791.
22. 22 Krop, IE, Kim, S, González-Martín, A, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15 (2014), 689–699.
23. 23 Wildiers, H, Kim, S, Gonzalez-Martin, A, et al. Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study. Cancer Res 76 (2016), S5–05 (abstr).
24. 24 Cosson, VF, Ng, VW, Lehle, M, Lum, BL, Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 73 (2014), 737–747.
25. 25 National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines): gastric cancer. Version 3. 2016. http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf, 2016 (accessed Nov 23).
26. 26 Jenkins, M, Stone, A, Jennison, C, An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharm Stat 10 (2011), 347–356.
27. 27 Chon, HJ, Rha, SY, Im, CK, et al. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat 41 (2009), 196–204.
28. 28 Kulke, MH, Muzikansky, A, Clark, J, et al. A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest 24 (2006), 346–350.
29. 29 Barok, M, Joensuu, H, Isola, J, Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res, 16, 2014, 209.
30. 30 Loganzo, F, Tan, X, Sung, M, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther 14 (2015), 952–963.
31. 31 Peng, Z, Zou, J, Zhang, X, et al. HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. Chin J Cancer Res 27 (2015), 163–171.
32. 32 Ishimine, Y, Goto, A, Watanabe, Y, et al. Loss of HER2 positivity after trastuzumab in HER2-positive gastric cancer: is change in HER2 status significantly frequent?. Case Rep Gastrointest Med, 2015, 2015, 132030.
33. 33 Janjigian, YY, Riches, JC, Ku, GY, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab. J Clin Oncol, 33, 2015, 63 (suppl 3)(abstr).
34. 34 Erickson, HK, Park, PU, Widdison, WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66 (2006), 4426–4433.
35. 35 Li, F, Emmerton, KK, Jonas, M, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res 76 (2016), 2710–2719.